Nutromics Names Plaxco CSO to Bolster DNA Sensing Platform Expansion

Nutromics has appointed Professor Kevin Plaxco as its new Chief Scientific Officer, a move designed to bolster the expansion of its DNA-based sensing platform. The company is targeting a product launch in 2027 and plans to extend its wearable technology to additional biomarkers and therapeutic targets. Professor Plaxco, who invented the core sensing technology, will lead this strategic expansion.

### Money Play This appointment is a strategic development for Nutromics as it prepares for commercialization. Investors focused on biotechnology and advanced diagnostics may monitor the company's progress in extending its platform and its upcoming product launch in 2027.

## Catalyst Analysis: Executive Appointment Driving Platform Expansion Professor Kevin Plaxco has joined Nutromics as Chief Scientific Officer, a role that will see him focus on expanding the company's DNA-based sensing technology. Nutromics, which is backed by research demonstrating its technology in humans, is preparing to launch its first product in 2027 and aims to extend its wearable platform. Plaxco's expertise is expected to accelerate the development of the platform into new applications, potentially targeting biomarkers such as creatinine and lactate, in addition to drugs like vancomycin.

Professor Plaxco brings significant scientific background to the role, having invented the underlying Electrochemical Aptamer-Based (EAB) sensing technology and co-authored nearly 300 papers and a dozen patents. His appointment follows his tenure as an advisor and head of the company's Biosensor Advisory Board, where he played a key role in major milestones, including a clinical trial published in Nature Biotechnology. The company believes his hands-on guidance will be crucial in broadening the applications of their technology for both hospital and home use.

## $TICKER Technical Analysis & Key Risk Watch

Key levels for $META+WL (educational): R2 $570.90 · R1 $560.66 · last $559.02 · S1 $558.00 · S2 $546.30.

As Nutromics is a private entity, no public ticker information or live market context is available.

### Sector Ripple / Impact on Biotechnology Nutromics operates within the biotechnology sector, focusing on DNA-based sensing technologies. While no direct ripple effect on other specific tickers is immediately evident from this appointment alone, the advancement of such platforms could influence investor interest in companies developing innovative diagnostic and monitoring solutions.